NVS On Other Exchanges
New York
SIX Swiss Ex
SIX Swiss Ex
text size: T | T
Back to Snapshot
Company Description

Contact Info

Lichtstrasse 35

Basel, 4056


Phone: 41 61 324 11 11

Fax: 41 61 324 80 01

rkets protein- or other biotechnology-based products known as biosimilars and provides biotechnology manufacturing services to other companies. In Oncology Injectables, Sandoz division develops, manufactures, and markets cytotoxic products for the hospital market. The Sandoz division develops, produces, and markets finished dosage form medicines, as well as intermediary products, including active pharmaceutical ingredients. The Sandoz division’s portfolio primarily includes differentiated products, such as MS treatment Glatopa (glatiramer acetate injection), the cardiovascular polypill Sincronium (acetylsalicylic acid, atorvastatin and ramipril), and the pain medication fentanyl, which is difficult to manufacture because its delivery mechanism is a transdermal patch. Its differentiated products also include biosimilars comprising Omnitrope, a human growth hormone; Binocrit, an erythropoiesis-stimulating agent used to treat anemia; and filgrastim for neutropenia under the brand names Zarzio outside the U.S. and Zarxio in the U.S. In 2015, the Sandoz division’s key product launches in the U.S. included Glatopa, the generic version of Teva's Copaxone 20mg (glatiramer acetate injection); the biosimilar Zarxio (filgrastim-sndz); and budesonide inhalation suspension (Astra Zeneca's Pulmicort Respules), as well as authorized generic versions of the The Medicine Company's Angiomax (bivalirudin); and its Pharmaceutical division's Exelon Patch (rivastigmine patch). In 2015, the Sandoz division’s key product launches in various European countries included aripiprazole TAB (Atsuka's Abilify); duloxetine (Eli Lilly's Cymbalta); pregabalin HGC (Pfizer's Lyrica); and valganciclovir FCT (Roche's Valcyte). In addition, the global rollout of AirFluSal Forspiro continued with launches across Europe. Sales and Marketing The Sandoz division sells a portfolio of generic pharmaceutical products and biosimilars to wholesalers, pharmacies, hospitals, and other healthcare outlets. Its principal markets include the U.S. and Europe. Discontinued Operations Vaccines and Diagnostics division In March 2015, the company completed the divestment of its Vaccines division (excluding its influenza vaccines business) to GSK. In July 2015, the company completed the divestment of its influenza vaccines business to CSL Limited. Consumer Health In January 2015, the company completed the divestment of its Animal Health Division to Eli Lilly and Company. In March 2015, the company completed the divestment of its OTC division, which the company contributed to a new consumer healthcare joint venture with GSK, of which the company owns 36.5%. Significant Events In May 2016, Novartis announced changes to focus its Pharmaceuticals Division by creating two business units reporting to the CEO: Novartis Pharmaceuticals and Novartis Oncology. These business units would form the Innovative Medicines Division at Novartis. The leader of each business would join the Executive Committee of Novartis (ECN) effective July 1, 2016. In June 2016, Xencor, Inc. announced that it has entered into a collaboration and license agreement with Novartis to develop and commercialize novel therapeutics, including XmAb14045 expected to begin clinical development for acute myeloid leukemia in 2016; and XmAb 13676 also expected to begin clinical development for B-cell malignancies in 2016. In September 2016, Cerulean Pharma said it formed a strategic collaboration with Novartis to develop nanoparticle-drug conjugates directed at up to five cancer tumor targets. Under the collaboration, Cerulean's Dynamic Tumor Targeting technology will be combined with Novartis' proprietary compounds. History Novartis AG was founded in 1895.


The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

NVS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NVS.
View Industry Companies

Industry Analysis


Industry Average

Valuation NVS Industry Range
Price/Earnings 27.2x
Price/Sales 3.6x
Price/Book 2.5x
Price/Cash Flow 29.2x
TEV/Sales 3.3x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact NOVARTIS AG-SPONSORED ADR, please visit www.novartis.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.